ClinicalTrials.gg
CompletedNCT03461406Updated Apr 14, 2023Results posted

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

A Phase 3 interventional study of Fibrin Sealant Grifols and EVICEL in Excessive Bleeding During Surgery, sponsored by Instituto Grifols, S.A.. Completed at 40 sites in 10 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2023-04-14.

Sponsored by Instituto Grifols, S.A. (part of Grifols) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The objective of the study is to evaluate if FS Grifols is non-inferior to EVICEL® in terms of the percentage of participants achieving hemostasis at the target bleeding site (TBS) by 4 minutes (T4) from the start of treatment application (TStart) with no occurrence of rebleeding until the completion of the surgical closure by layers of the exposed surgical field containing the TBS (TClosure).

Read the detailed description

This is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during surgery. Approximately 172 pediatric participants will be enrolled and will be randomly allocated in a 1:1 ratio into 1 of 2 treatment groups: FS Grifols or EVICEL. Enrollment will be monitored by surgery type to ensure at least 50% of the surgical procedures are hepatic.

A specific bleeding site will be defined as the TBS when it is determined by the investigator (the surgeon) that control of bleeding by conventional surgical techniques (including suture, ligature, and cautery) is ineffective or impractical and requires an adjunct treatment to achieve hemostasis.

When the TBS is identified, the investigator will record the precise anatomical location of the TBS, rate the intensity of the bleeding at the TBS (Grade 1-4 according to a 5-point validated bleeding severity scale), and record the size of the approximate bleeding surface, (small, medium, and large). For soft tissue surgery only, the investigator will also record the type of soft tissue (ie, fat, muscle, or connective tissue). In this clinical trial, only participants with a TBS with bleeding of Grade 1 (mild) or Grade 2 (moderate) intensity will be enrolled.

This study includes a Screening Visit to determine participant eligibility, a Baseline Visit, the Surgical Procedure (Day 1), and Post-operative assessments at Days 1, 4, and 30. The total duration of a participant's participation in this study is expected to be no longer than 2 months from the Screening Visit to the Post-operative Day 30 Visit.

02

Conditions studied

  • Excessive Bleeding During Surgery
03

In context

Lead sponsor

Instituto Grifols, S.A. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-operative:

  1. Less than 18 years of age.
  2. Requires an elective (non-emergent), open (non-laparoscopic), pelvic, abdominal, or thoracic (non-cardiac) surgical procedure.
  3. Participant and/or participant's legal guardian is willing to give permission for the participant to participate in the clinical trial and provide written for the participant. In addition, assent must be obtained from pediatric participants who possess the intellectual and emotional ability to comprehend the concepts involved in the clinical trial.

    Intra-operative:

  4. Presence of an appropriate (as defined in inclusion criterion 5) parenchymous or soft tissue TBS identified intra-operatively by the investigator (the surgeon).
  5. TBS has Grade 1 (mild) or Grade 2 (moderate) bleeding intensity according to the investigator's (the surgeon's) judgment. The intensity of the bleeding at the TBS will be rated by the investigator using the 5-point validated bleeding severity scale.

Exclusion criteria

Exclusion Criteria:

Pre-operative:

  1. Admitted for trauma surgery.
  2. Unwilling to receive blood products.
  3. Known history of severe (eg, anaphylactic) reaction to blood products.
  4. Known history of intolerance to any of the components of the product (IP).
  5. Female participants who are pregnant, breastfeeding or, if of (ie, adolescent), unwilling to practice a highly effective method of .
  6. Previously enrolled in a clinical trial with FS Grifols.
  7. Currently participating, or during the study is planned to participate, in any other investigational device or medicinal product study without prior and explicit approval from the sponsor.

    Intra-operative:

  8. An appropriate parenchymous or soft tissue TBS (as defined in exclusion criteria 9 and 10) cannot be identified intra-operatively by the investigator (the surgeon).
  9. TBS has Grade 3 (severe) bleeding according to the investigator's (the surgeon's) judgment that cannot be controlled with conventional surgical techniques to Grade 1 or Grade 2 bleeding. The intensity of the bleeding at the TBS will be rated by the investigator using the 5-point validated bleeding severity scale.
  10. TBS is in an actively infected surgical field.
  11. Occurrence of major intra-operative complications that require resuscitation or deviation from the planned surgical procedure.
  12. Application of any topical hemostatic agent on the resection surface of parenchyma or soft tissue prior to application of the IP.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Fibrin Sealant Grifols

    Participants topically applied FS Grifols, which consisted of component 1: human fibrinogen (80 mg/mL) and component 2: human thrombin with calcium chloride (500 IU/mL) solutions filled in syringes and assembled on a syringe holder.

    Biological: Fibrin Sealant Grifols

  • Active comparator
    EVICEL

    Participants topically applied EVICEL, which consisted of component 1: Concentrate of human fibrinogen (BAC 2) (55-85 mg/mL) and component 2: human thrombin (800-1200 IU/mL) solutions. The 2 components (BAC2 and thrombin) were mixed and applied topically.

    Biological: EVICEL

Interventions

  • BiologicalFibrin Sealant Grifols

    The FE Grifols solution was applied topically via drip or spray application.

    Also known as: FS Grifols

  • BiologicalEVICEL

    Drug pages: Fibrinogen · Thrombin

    The EVICEL solution was applied topically via drip or spray application.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4)

    Hemostasis is defined as Grade 0 bleeding per 5-point validated bleeding severity scale (0=no bleeding and 4=Unidentified or inaccessible spurting or gush) at the target bleeding site (TBS) according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin.

    Time frame: From start of treatment until 4 minutes after treatment start (Day 1)

Secondary outcomes

  1. Cumulative Percentage of Participants Achieving Hemostasis at the TBS by the 7 Minutes After Treatment Start (T7)

    Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T7 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.

    Time frame: From start of treatment to 7 minutes after start of treatment (Day 1)

  2. Cumulative Percentage of Participants Achieving Hemostasis at the Target Bleeding Site by 10 Minutes After Treatment Start (T10)

    Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T10 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.

    Time frame: From start of treatment to 10 minutes after start of treatment (Day 1)

  3. Percentage of Participants With Treatment Failures

    Participants were considered treatment failures if there is a. persistent bleeding at the TBS beyond T4 b. Grade 3 or Grade 4 breakthrough bleeding from the TBS that jeopardizes participant safety according to the investigator's judgment at any moment during the 10-minute observational period and until TClosure c. Use of alternative hemostatic treatments or maneuvers (other than the study treatment) at the TBS during the 10-minute observational period and until TClosure, or use of study treatment at the TBS beyond T4 and until TClosure d. Rebleeding (Grade ≥1) at the TBS after the assessment of the primary efficacy endpoint at T4 and until TClosure.

    Time frame: From start of treatment to 10 minutes after start of treatment and until the time of completion of surgical closure (Day 1)

07

Results

Posted Apr 7, 2023

Participant flow

Participants took part in the study at 18 sites in the United States, Bulgaria, France, Hungary, Romania, Serbia, and United Kingdom, from 18 January 2019 (first participant enrolled to receive the study drug) to 20 May 2022 (last participant completed).

Participant flow — Overall Study
MilestoneFibrin Sealant GrifolsEVICEL
Started9591
Parenchymous surgery4643
Soft tissue surgery4544
Safety population9187
Completed8784
Not completed87
Withdrew: Death12
Withdrew: Consent withdrawn by participant01
Withdrew: Screen failure31
Withdrew: Reason not specified13
Withdrew: Lost to follow-up30

Outcome measures

PrimaryPercentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4)

Hemostasis is defined as Grade 0 bleeding per 5-point validated bleeding severity scale (0=no bleeding and 4=Unidentified or inaccessible spurting or gush) at the target bleeding site (TBS) according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin.

Time frame:
From start of treatment until 4 minutes after treatment start (Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start (T4)
percentage of participantsFibrin Sealant GrifolsEVICEL
Parenchymous Surgery100.0100.0
Soft Tissue Surgery93.390.9
Statistical analysis
  • Fibrin Sealant Grifols vs EVICEL · Cochran-Mantel-Haenszel · p = < 0.001 · Relative risk: 1 · 95% CI 0.92 to 1.09
  • Fibrin Sealant Grifols vs EVICEL · Cochran-Mantel-Haenszel · p = < 0.001 · Relative risk: 1.03 · 95% CI 0.91 to 1.16
SecondaryCumulative Percentage of Participants Achieving Hemostasis at the TBS by the 7 Minutes After Treatment Start (T7)

Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T7 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.

Time frame:
From start of treatment to 7 minutes after start of treatment (Day 1)
Reported as:
Number · percentage of participants
Cumulative Percentage of Participants Achieving Hemostasis at the TBS by the 7 Minutes After Treatment Start (T7)
percentage of participantsFibrin Sealant GrifolsEVICEL
Parenchymous Surgery100.0100.0
Soft Tissue Surgery100.0100.0
Statistical analysis
  • Fibrin Sealant Grifols vs EVICEL · Cochran-Mantel-Haenszel · p = < 0.001 · Relative risk: 1 · 95% CI 0.92 to 1.09
  • Fibrin Sealant Grifols vs EVICEL · Cochran-Mantel-Haenszel · p = < 0.001 · Relative risk: 1 · 95% CI 0.92 to 1.09
SecondaryCumulative Percentage of Participants Achieving Hemostasis at the Target Bleeding Site by 10 Minutes After Treatment Start (T10)

Hemostasis is defined as Grade 0 bleeding at the TBS according to the investigator's (surgeon's) judgment, so that the surgical closure of the exposed field could begin. The cumulative percentage of participants achieving hemostasis at the TBS by the time points of T10 defined as an absence/cessation of bleeding (Grade 0) at the TBS by that time point without occurrence of rebleeding, Grade 3 or Grade 4 bleeding, use of alternative hemostatic treatment, and reapplication of study treatment after T4 and until TClosure.

Time frame:
From start of treatment to 10 minutes after start of treatment (Day 1)
Reported as:
Number · percentage of participants
Cumulative Percentage of Participants Achieving Hemostasis at the Target Bleeding Site by 10 Minutes After Treatment Start (T10)
percentage of participantsFibrin Sealant GrifolsEVICEL
Parenchymous Surgery97.8100.0
Soft Tissue Surgery100.0100.0
Statistical analysis
  • Fibrin Sealant Grifols vs EVICEL · Cochran-Mantel-Haenszel · p = < 0.001 · Relative risk: 0.98 · 95% CI 0.94 to 1.02
  • Fibrin Sealant Grifols vs EVICEL · Cochran-Mantel-Haenszel · p = < 0.001 · Relative risk: 1 · 95% CI 0.92 to 1.09
SecondaryPercentage of Participants With Treatment Failures

Participants were considered treatment failures if there is a. persistent bleeding at the TBS beyond T4 b. Grade 3 or Grade 4 breakthrough bleeding from the TBS that jeopardizes participant safety according to the investigator's judgment at any moment during the 10-minute observational period and until TClosure c. Use of alternative hemostatic treatments or maneuvers (other than the study treatment) at the TBS during the 10-minute observational period and until TClosure, or use of study treatment at the TBS beyond T4 and until TClosure d. Rebleeding (Grade ≥1) at the TBS after the assessment of the primary efficacy endpoint at T4 and until TClosure.

Time frame:
From start of treatment to 10 minutes after start of treatment and until the time of completion of surgical closure (Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Failures
percentage of participantsFibrin Sealant GrifolsEVICEL
Parenchymous Surgery00
Soft Tissue Surgery00

Adverse events

Collected over From signing informed consent form up to 7 days post study completion (Up to approximately 47 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fibrin Sealant Grifols1/91 (1.1%)8/91 (8.8%)20/91 (22%)
EVICEL2/87 (2.3%)9/87 (10.3%)13/87 (14.9%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventFibrin Sealant GrifolsEVICEL
Anaphylactic shockImmune system disorders2/910/87
Post procedural haemorrhageInjury, poisoning and procedural complications0/911/87
Cardiac arrestCardiac disorders1/911/87
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/911/87
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders0/911/87
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders0/911/87
PancytopeniaBlood and lymphatic system disorders0/911/87
AscitesGastrointestinal disorders0/911/87
Ileus paralyticGastrointestinal disorders0/911/87
Respiratory syncytial virus infectionInfections and infestations0/911/87
Most frequent other events
Showing 10 of 38
Most frequent other events
EventFibrin Sealant GrifolsEVICEL
PyrexiaGeneral disorders0/915/87
VomitingGastrointestinal disorders5/913/87
AnaemiaBlood and lymphatic system disorders2/913/87
NauseaGastrointestinal disorders1/912/87
HypertensionVascular disorders2/910/87
Wound dehiscenceInjury, poisoning and procedural complications2/910/87
Abdominal distensionGastrointestinal disorders2/910/87
Mechanical ventilation complicationInjury, poisoning and procedural complications0/911/87
Haemoglobin decreasedInvestigations1/911/87
BronchospasmRespiratory, thoracic and mediastinal disorders1/911/87

Baseline characteristics

Intent-to-Treat (ITT) population included all participants who were randomized, regardless of meeting intra-operative enrollment criteria and regardless of whether the IP was administered to the participant.

Age, Continuous
Age, Continuous(years)Fibrin Sealant GrifolsEVICELTotal
Mean8.43 ± 6.1088.84 ± 6.3208.63 ± 6.199
Sex: Female, Male
Sex: Female, Male(Participants)Fibrin Sealant GrifolsEVICELTotal
Female403070
Male5561116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fibrin Sealant GrifolsEVICELTotal
Hispanic or Latino131124
Not Hispanic or Latino8280162
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fibrin Sealant GrifolsEVICELTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American628
White8689175
More than one race101
Unknown or Not Reported101
08

Study locations

40 sites
  • Lurie Childrens Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Michigan
    Michigan Center, Michigan 48109, United States
  • The Urological Institute of Northeastern New York
    Albany, New York 12208, United States
  • Columbia Medical Center
    New York, New York 10032, United States
  • St. Christophers Hospital
    Philadelphia, Pennsylvania 19134, United States
  • MUSC Health-Children's Hospital
    Charleston, South Carolina 29425, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38163, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • El Paso Childrens Hospital
    El Paso, Texas 79905, United States
  • Memorial Hermann Memorial City
    Houston, Texas 77024, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Carilion Children's Pediatric Surgery
    Roanoke, Virginia 24013, United States
  • MHAT City clinic - Sveti Georgi
    Montana, 3400, Bulgaria
  • UMHAT Dr. Georgi Stranski
    Pleven, 5800, Bulgaria
  • UMHAT Sveti Georgi
    Plovdiv, 4001, Bulgaria
  • UMHAT Kanev
    Ruse, 7000, Bulgaria
  • UMHATEM N.I.Pirogov
    Sofia, 1606, Bulgaria
  • UMHAT Prof. Dr. Stoyan Kirkovich
    Stara Zagora, 6000, Bulgaria
  • British Columbia's Children's Hospital
    Vancouver, 4480, Canada
  • Hôpitaux Pédiatriques de Nice CHU-Lenval
    Nice, 6200, France
  • Hôpital Armand Trousseau - APHP
    Paris, 75012, France
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Semmelweis University, 2nd Dpt of Paediatrics
    Budapest, 1094, Hungary
  • Heim Pál Pediatric Hospital
    Budapest, H-1089, Hungary
  • University of Debrecen Clinical Center, Pediatric Clinic No. I.
    Debrecen, H-4032, Hungary
  • Petz Aladár County Teaching Hospital, Department of Pediatric Surgery
    Győr, H-9023, Hungary
  • University of Pécs Clinical Centre, Pediatric Clinic
    Pécs, H-7623, Hungary
  • Spitalul Clinic de Urgenta pentru Copii "Maria Sklodowska Curie"
    Bucarest, 041434, Romania
  • Spitalul Clinic de Urgenta pentru Copii "Grigore Alexandrescu"
    Bucharest, 010623, Romania
  • Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca
    Cluj-Napoca, 400370, Romania
  • Spitalul Clinic de Urgenta pentru Copii "Sfanta Maria"
    Iasi, 700309, Romania
  • Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu"
    Timişoara, 300011, Romania
  • University Children' s Hospital
    Belgrade, 11000, Serbia
  • Mother and Child Healthcare Institute of Serbia "Dr Vukan Cupic"
    Belgrade, 11070, Serbia
  • Clinical Centre Nis, Clinic for Pediatric Surgery and Orthopedics
    Nis, 18000, Serbia
  • Insititute for Health Protection of Children and Youth
    Novi Sad, 21000, Serbia
  • Karolinska Universitetssjukhuset
    Huddinge, Stockholm 14186, Sweden
  • Birmingham Children's Hospital NHS Foundation Trust
    Birmingham, B46NH, United Kingdom
  • Clesea & Westmisnter Hospital
    London, SW109NH, United Kingdom
  • Southampton Children's Hospital
    Southampton, SO166YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Apr 2022, 38 months.

Results were first posted in Apr 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2018
First posted
Mar 12, 2018
StartActual
Jan 18, 2019
Primary completionActual
Apr 15, 2022
CompletionActual
May 20, 2022
Results first posted
Apr 7, 2023
Last update
Apr 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03461406
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Jan 18, 2019
Primary completion
Apr 15, 2022
Completion
May 20, 2022
Results posted
Apr 7, 2023
Last update
Apr 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion